High-risk
neuroblastoma is associated with low long-term survival rates due to recurrence or
metastasis.
Retinoids, including
13-cis-retinoic acid (13cRA), are commonly used for the treatment of high-risk
neuroblastoma after myeloablative
therapy; however, there are significant side effects and resistance rates. In this study, we demonstrated that 13cRA has a better antiproliferative effect in MYCN-amplified
neuroblastoma cells than in MYCN-nonamplified
neuroblastoma cells. In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of
toll-like receptor 3 (TLR3) and mitochondrial
antiviral-signaling
protein (MAVS) expression in a time-dependent manner. Furthermore,
poly (I:C), a synthetic agonist of TLR3, effectively synergized with 13cRA to enhance antiproliferative effects through upregulation of the innate immune signaling and the mitochondrial stress response, leading to augmentation of the apoptotic response in 13cRA-responsive
cancer cells. In addition, the 13cRA/
poly (I:C) combination induced neural differentiation through activation of
retinoic acid receptors beta (RAR-β), restoring expression of α-
thalassemia/
mental retardation syndrome X-linked (
ATRX) protein, and inhibiting vessel formation, leading to retarded
tumor growth in a mouse xenograft model. These results suggest that the combination of
poly (I:C) and RA may provide synergistic therapeutic benefits for treatment of patients with high-risk
neuroblastoma.